Correction of Anaemia and Progression of Renal Failure on Transplanted Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2010

Conditions
AnaemiaRenal TransplantationKidney Failure
Interventions
DRUG

Neorecormon

Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B

Trial Locations (20)

13385

Hôpital de la Conception, Marseille

14033

Hôpital Clémenceau, Caen

33076

Hôpital Pellegrin, Bordeaux

Hôpital Rangueil, Toulouse

35033

Hôpital Pontchaillou, Rennes

37044

CHU de Tours - Hôpital Bretonneau, Tours

38043

Hôpital de la Tronche, Grenoble

51092

Hôpital Maison Blanche, Reims

54500

Hôpital Brabois, Vandœuvre-lès-Nancy

59037

Hôpital Calmette, Lille

63003

CHU Clermont Ferrand - Hôpital Gabriel Monpied, Clermont-Ferrand

67091

Hôpital Civil, Strasbourg

75743

Hôpital Necker - Enfants Malades, Paris

76230

Hôpital de Bois Guillaume, Bois-Guillaume

80000

Hôpital Sud, Amiens

86021

Hôpital de la Milétrie, Poitiers

87052

Hôpital Dupuytren, Limoges

92151

Hôpital Foch, Suresnes

94010

Hôpital Henri Mondor, Créteil

06002

Hôpital Pasteur, Nice

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Centre Hospitalier Universitaire, Amiens

OTHER

NCT00396435 - Correction of Anaemia and Progression of Renal Failure on Transplanted Patients | Biotech Hunter | Biotech Hunter